Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lorlatinib

- PMLiVE

Roche’s Tecentriq misses survival mark in frontline NSCLC

Keytruda proving hard to beat

- PMLiVE

Pfizer’s Prevnar-13 successor takes aim at Merck rival

Rivals look to broaden coverage across strains

- PMLiVE

MSD wins key EU approval for Keytruda, Alimta combo

Decision keeps Keytruda well ahead of rival Tecentriq

- PMLiVE

FDA gives Loxo breakthrough tag for second cancer drug

US regulatory body to expect a NDA for LOXO-292 in late 2019

- PMLiVE

Pfizer abandons antibody for Duchenne

Latest to fail in myostatin inhibitor class

AstraZeneca AZ

AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

Japanese regulator clears the drug for first-line use in NSCLC

- PMLiVE

Roche’s Alecensa backed by China’s National Drug Administration

Approved to treat ALK-positive lung cancer

- PMLiVE

Pfizer signs mRNA flu vaccine deal with BioNTech

Pharma giant will take on development and commercial responsibility for candidates

- PMLiVE

Pfizer CEO reckons rebates will disappear, and that’s a positive

The move also has the support of FDA Commissioner Scott Gottlieb

- PMLiVE

Novartis follows Pfizer and freezes US prices this year

And still expects revenues to come in at the high end of expectations for 2018

- PMLiVE

Pfizer enters late-stage haemophilia B gene therapy trial

Race is on to free patients of regular injections

- PMLiVE

Pfizer builds gap between pharma and consumer health units

Its consumer health division will become a standalone unit after lack of buyer interest

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links